查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041843

陰道炎治療市場預測至2034年－按疾病類型、治療方法、通路和地區分類的全球分析

Vaginitis Therapeutics Market Forecasts to 2034 - Global Analysis By Disease Type, By Treatment, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，到 2026 年，全球陰道炎治療市場規模將達到 47 億美元，預計在預測期內將以 10.3% 的複合年成長率成長，到 2034 年將達到 103 億美元。

陰道炎藥物治療是指旨在治療陰道發炎或感染疾病（即陰道炎）的醫療介入措施。常見原因包括細菌、真菌或病毒感染疾病，治療通常涉及抗生素、抗真菌藥物物或抗病毒藥物。此外，控制潛在因素（例如荷爾蒙失衡和刺激物）也至關重要。個人化護理可能包括局部和口服藥物、生活方式調整以及解決能夠緩解症狀和恢復陰道健康的因素。

根據美國疾病管制與預防中心統計，美國約有30%的女性經常罹患陰道炎。

人們對女性健康和陰道感染疾病的認知不斷提高

女性健康和陰道感染疾病意識的提升是推動陰道炎治療的重要動力。這促進了積極主動的醫療保健方式，鼓勵女性及早識別症狀、及時就醫並採取預防措施。這種意識的提高促使更多宣傳活動開展，促進更開放的討論，並減少圍繞陰道健康問題的污名化。最終，這改善了女性的就醫行為，促進了早期診斷、及時干預，並提高了對有效治療方法的需求。

醫療保健服務獲取限制

醫療資源匱乏是治療陰道炎的一大障礙。這包括許多方面，尤其是在農村地區和醫療資源匱乏地區，醫療基礎設施不足，導致醫療機構和專家短缺。此外，經濟困難和醫療資源分配不均也使得部分患者無法及時獲得診斷和治療。這種限制加劇了診斷和治療的延誤，阻礙了關鍵訊息和治療方法的傳播，最終影響了對陰道炎患者群體的有效管理。

遠端醫療的益處

遠端醫療的普及，尤其是其與遠距離診斷和治療的融合，正在為陰道炎治療市場創造新的機會。隨著遠端醫療的擴展，精準輻射監測工具的需求也日益成長。這些設備對於確保患者安全至關重要，它們能夠遠端評估遠距遠端醫療過程中（包括影像檢查和放射治療）的輻射暴露。遠端保健環境下的輻射探測技術創新，為企業提供了開發攜帶式、易用且高精度檢測器的機會，從而滿足這一不斷發展的市場需求。

臨床試驗中的挑戰

教育和資源的匱乏阻礙了適當輻射安全措施的實施以及對探測技術的理解。這增加了患者和醫護人員輻射過量暴露的風險，並可能對其健康造成影響。此外，缺乏嚴格的監管和基礎設施投資不足加劇了這一問題，可能導致輻射相關健康併發症的發生率上升，並由於對先進探測解決方案的需求不足而阻礙市場成長。

新冠疫情的影響：

新冠疫情透過改變醫療保健的優先事項影響了市場。隨著醫療系統將重點放在應對疫情上，關注點和資源轉向了陰道炎等非緊急疾病。醫療服務取得、供應鏈和病患行為的中斷也影響了就診和治療模式，從而在疫情期間改變了陰道炎治療市場的動態。

在預測期內，處方藥領域預計將成為最大的細分市場。

預計在預測期內，處方藥市場將成為最大的細分市場，這主要受慢性病盛行率上升和對專業醫療干預需求日益成長的推動。公眾健康意識的提高也促使人們對用於治療特定疾病的處方藥的需求激增。此外，監管部門的核准和藥物研發的進步也提升了該細分市場的重要性。

在預測期內，線上藥局領域預計將呈現最高的複合年成長率。

預計在預測期內，線上藥局領域將實現高速成長，這主要得益於數位化技術的進步以及醫療服務便利性和可近性的提升。隨著消費者越來越重視在家購藥的便利性，線上藥局提供了極具吸引力的解決方案。遠端醫療的普及和電子商務的進步共同推動了該領域的快速成長。

市佔率最大的地區：

北美在陰道炎治療市場佔據主導地位，這主要歸功於其先進的醫療保健基礎設施、較高的意識層級以及對女性健康的高度重視。該地區主導的市場佔有率還得益於其完善的研發體系、健全的法規結構以及積極採用創新治療方法的策略。陰道炎發病率的不斷上升以及人口老化，推動了對有效療法的需求，進一步鞏固了北美在陰道炎治療市場中佔據最大市場佔有率的關鍵地位。

複合年成長率最高的地區：

在亞太地區，由於公眾健康意識的提高、醫療基礎設施的完善以及對女性健康日益成長的關注，市場正經歷顯著成長。醫療服務可近性的改善、生活方式的改變以及陰道炎盛行率的上升等因素，都推動了該地區市場的穩定擴張。此外，醫學研究和技術的進步，以及政府的支持，為創新型陰道炎療法的研發和推廣創造了有利環境，從而顯著促進了亞太地區市場的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球陰道炎治療市場：依疾病類型分類

  • 萎縮性陰道炎
  • 細菌性陰道炎（BV）
  • 滴蟲病
  • 外陰陰道念珠菌症（VVC）
  • 其他疾病類型

第6章：全球陰道炎治療市場：依治療方法分類

  • 處方藥
  • 自然療法和草藥療法
  • 非處方藥
  • 益生菌和陰道栓劑

第7章 全球陰道炎治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他分銷管道

第8章：全球陰道炎治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Astellas Pharma
  • AstraZeneca PLC
  • Bausch Health Companies Inc
  • Bayer AG
  • Biocon Limited
  • Cipla Inc.
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
Product Code: SMRC24909

According to Stratistics MRC, the Global Vaginitis Therapeutics Market is accounted for $4.7 billion in 2026 and is expected to reach $10.3 billion by 2034 growing at a CAGR of 10.3% during the forecast period. Vaginitis therapeutics encompasses medical interventions aimed at treating inflammation or infection of the vagina, a condition known as vaginitis. Common causes include bacterial, fungal or viral infections and treatment often involves antimicrobial medications, antifungals, or antivirals. Additionally, managing underlying factors like hormonal imbalances or irritants is crucial. Personalized care may include topical or oral medications, lifestyle modifications and addressing contributing factors to alleviate symptoms and restore vaginal health.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals.

Market Dynamics:

Driver:

Heightened awareness about women's health and vaginal infections

Increased awareness about women's health and vaginal infections acts as a pivotal driver in vaginitis therapeutics. It fosters a proactive approach to healthcare, encouraging women to recognize symptoms early, seek prompt medical attention and adopt preventive measures. This awareness promotes education initiatives, facilitates open discussions and reduces stigma surrounding vaginal health issues. Consequently, it leads to improved healthcare-seeking behaviour, earlier diagnosis, and timely intervention, driving the demand for effective therapies.

Restraint:

Limited healthcare access

Limited healthcare access serves as a significant restraint in vaginitis therapeutics. It encompasses various barriers such as inadequate healthcare infrastructure, especially in rural or underserved areas, leading to reduced availability of medical facilities and specialists. Additionally, financial constraints and disparities in access prevent some individuals from seeking timely diagnosis and treatment. This limitation exacerbates underdiagnosis, delays in care and impedes the dissemination of crucial information and treatments, thereby restricting effective management of vaginitis among affected populations.

Opportunity:

Increasing adoption of telemedicine facilitates

The growing adoption of telehealth presents an opportunity in the vaginitis therapeutics market due to its integration with remote diagnostics and treatments. As telehealth expands, there is a need for accurate radiation monitoring tools. These devices become crucial in ensuring patient safety by remotely assessing radiation exposure during telemedicine sessions involving imaging or radiation therapies. Innovations in radiation detection technologies catering to telehealth settings offer a chance for companies to develop portable, user-friendly, and precise detectors, thereby tapping into this evolving market demand.

Threat:

Clinical trial challenges

Limited education and resources hinder the adoption of proper radiation safety measures and the understanding of detection technologies. This can lead to increased risks of overexposure to radiation for both patients and healthcare workers, impacting their health. Additionally, the absence of stringent regulations and insufficient infrastructure investment further exacerbate this issue, potentially resulting in higher incidences of radiation-related health complications and impeding the market's growth due to a lack of demand for advanced detection solutions.

Covid-19 Impact:

The COVID-19 pandemic has influenced the market by altering healthcare priorities. With healthcare systems focusing on combating the pandemic, attention and resources shifted away from non-emergency conditions like vaginitis. Disruptions in healthcare access, supply chains, and patient behaviour also affected diagnosis and treatment-seeking patterns, impacting the market dynamics for vaginitis therapeutics during the pandemic period.

The prescription drugs segment is expected to be the largest during the forecast period

The prescription drugs segment is anticipated to be the largest during the forecast period owing to the growing prevalence of chronic diseases and the increasing need for specialized medical interventions. As healthcare awareness rises, there is a surge in demand for prescription medications to address specific health conditions. Additionally, regulatory approvals and advancements in pharmaceutical research contribute to the prominence of this segment.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to achieve a high growth rate during the forecast period due to increasing digitalization, convenience and accessibility of healthcare services. As consumers prioritise the ease of purchasing medications from the comfort of their homes, online pharmacies offer a compelling solution. The adoption of telemedicine, coupled with advancements in e-commerce, fosters the rapid growth of this segment.

Region with largest share:

North America is positioned to dominate the market, primarily attributed to advanced healthcare infrastructure, high awareness levels, and a robust emphasis on women's health. The region's leading market share is further propelled by well-established research and development activities, a strong regulatory framework, and a proactive approach toward adopting innovative therapies. Increasing incidences of vaginitis, coupled with a growing aging population, contribute to the demand for effective therapeutics, reinforcing North America's pivotal role in capturing the largest market share in the vaginitis therapeutics market.

Region with highest CAGR:

The Asia-Pacific region is experiencing significant growth in the market due to rising awareness, increasing healthcare infrastructure and a growing emphasis on women's health. Factors such as improved access to healthcare services, changing lifestyles, and a rising incidence of vaginitis contribute to the region's poised expansion. Additionally, advancements in medical research and technology, coupled with supportive government initiatives, create a favourable environment for the development and adoption of innovative vaginitis therapeutics, driving substantial market growth in the Asia-Pacific region.

Key players in the market

Some of the key players in Vaginitis Therapeutics Market include Astellas Pharma, AstraZeneca PLC, Bausch Health Companies Inc, Bayer AG, Biocon Limited, Cipla Inc., Ferring Pharmaceuticals, GlaxoSmithKline plc, Hologic, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Perrigo Company plc, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc.

Key Developments:

In January 2023, Astellas Pharma acquired Shionogi & Co.'s global women's health franchise, which includes the Vagifem vaginal ring for the treatment of recurrent vulvovaginal candidiasis (RVVC).

In May 2022, Bayer acquired FemTec, including Vagisan, a vaginal moisturizer. Additionally, Seres Therapeutics introduced SER-109, a microbiome-based therapy for recurrent vulvovaginal candidiasis (RVVC).

In April 2022, Pfizer introduced Daivobet, a topical cream combining steroids and vitamin D, designed to treat vulvovaginal candidiasis (VVC). Daivobet stands as the sole FDA-approved topical cream with this combination for VVC treatment.

Disease Types Covered:

  • Atrophic Vaginitis
  • Bacterial vaginosis (BV)
  • Trichomoniasis
  • Vulvovaginal Candidiasis (VVC)
  • Other Disease Types

Treatments Covered:

  • Prescription Drugs
  • Natural and Herbal Remedies
  • Over-the-counter (OTC) Drugs
  • Probiotics and Vaginal Suppositories

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaginitis Therapeutics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Atrophic Vaginitis
  • 5.3 Bacterial vaginosis (BV)
  • 5.4 Trichomoniasis
  • 5.5 Vulvovaginal Candidiasis (VVC)
  • 5.6 Other Disease Types

6 Global Vaginitis Therapeutics Market, By Treatment

  • 6.1 Introduction
  • 6.2 Prescription Drugs
  • 6.3 Natural and Herbal Remedies
  • 6.4 Over-the-counter (OTC) Drugs
  • 6.5 Probiotics and Vaginal Suppositories

7 Global Vaginitis Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Vaginitis Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Astellas Pharma
  • 10.2 AstraZeneca PLC
  • 10.3 Bausch Health Companies Inc
  • 10.4 Bayer AG
  • 10.5 Biocon Limited
  • 10.6 Cipla Inc.
  • 10.7 Ferring Pharmaceuticals
  • 10.8 GlaxoSmithKline plc
  • 10.9 Hologic, Inc.
  • 10.10 Johnson & Johnson
  • 10.11 Lupin Pharmaceuticals, Inc.
  • 10.12 Merck & Co., Inc.
  • 10.13 Mylan N.V.
  • 10.14 Novartis AG
  • 10.15 Perrigo Company plc
  • 10.16 Pfizer Inc.
  • 10.17 Sanofi
  • 10.18 Sun Pharmaceutical Industries Ltd.
  • 10.19 Teva Pharmaceutical Industries Ltd.
  • 10.20 TherapeuticsMD, Inc.

List of Tables

  • Table 1 Global Vaginitis Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 3 Global Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 4 Global Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 5 Global Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 6 Global Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 7 Global Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 8 Global Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 9 Global Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 10 Global Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 11 Global Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 12 Global Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 13 Global Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 14 Global Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 15 Global Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 16 Global Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 17 Global Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 18 North America Vaginitis Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 19 North America Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 20 North America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 21 North America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 22 North America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 23 North America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 24 North America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 25 North America Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 26 North America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 27 North America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 28 North America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 29 North America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 30 North America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 31 North America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 32 North America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 33 North America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 34 North America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 35 Europe Vaginitis Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 36 Europe Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 37 Europe Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 38 Europe Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 39 Europe Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 40 Europe Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 41 Europe Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 42 Europe Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 43 Europe Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 44 Europe Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 45 Europe Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 46 Europe Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 47 Europe Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 48 Europe Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 49 Europe Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 50 Europe Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 51 Europe Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 52 Asia Pacific Vaginitis Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 53 Asia Pacific Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 54 Asia Pacific Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 55 Asia Pacific Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 56 Asia Pacific Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 57 Asia Pacific Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 58 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 59 Asia Pacific Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 60 Asia Pacific Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 61 Asia Pacific Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 62 Asia Pacific Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 63 Asia Pacific Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 64 Asia Pacific Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 65 Asia Pacific Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 66 Asia Pacific Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 67 Asia Pacific Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 68 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 69 South America Vaginitis Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 70 South America Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 71 South America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 72 South America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 73 South America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 74 South America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 75 South America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 76 South America Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 77 South America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 78 South America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 79 South America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 80 South America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 81 South America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 82 South America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 83 South America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 84 South America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 85 South America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 86 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Country (2023-2034) ($MN)
  • Table 87 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 88 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) ($MN)
  • Table 89 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) ($MN)
  • Table 90 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) ($MN)
  • Table 91 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) ($MN)
  • Table 92 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) ($MN)
  • Table 93 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 94 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) ($MN)
  • Table 95 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) ($MN)
  • Table 96 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) ($MN)
  • Table 97 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) ($MN)
  • Table 98 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 99 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 100 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 101 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 102 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) ($MN)